Experts discuss evolving treatment strategies for metastatic castration-resistant prostate cancer, emphasizing personalized therapy and innovative options.
The Genomic Prostate Score (GPS) is being validated in the ProtecT trial to predict prostate cancer progression and treatment outcomes. ProtecT is a landmark phase 3 trial with over 1600 men, ...
The expert faculty emphasize the growing importance of multidisciplinary collaboration and workforce development as NMIBC management evolves to include systemic immunotherapies. The expert faculty ...
The first-ever guideline on genitourinary syndrome of menopause (GSM) was released, providing evidence-based guidance for managing this condition in urologic care. The FDA removed the black box ...
The study assessed descriptive sequencing and oncologic outcomes among patients receiving gene therapy for BCG-unresponsive NMIBC. Data presented at the 2025 Society of Urology Oncology Annual Meeting ...
The Decipher Genomic Classifier effectively predicts 2-year BCR in localized prostate cancer, especially in African American men, with an AUC of 0.889, increasing to 0.984 after adjustments. High-risk ...
The J9282 code for ZUSDURI facilitates billing and reimbursement, improving patient access to bladder cancer treatment. ZUSDURI, approved by the FDA in June 2025, is the first medication for recurrent ...
Hormonal changes influence fluid balance and bloating, increasing pressure within the pelvis. In this video, Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, founder of the Fosnight Center ...
GSK resubmitted an NDA for tebipenem pivoxil hydrobromide to the FDA for cUTI treatment, including pyelonephritis. The phase 3 PIVOT-PO trial showed tebipenem HBr's noninferiority to ...
Maxwell L. Sandberg, MD, highlights recent study findings on the role for perioperative systemic therapy for renal cell carcinoma with a tumor thrombus. Recent findings from a retrospective study ...
The Vanquish Water Vapor System and Hugo robotic-assisted surgery system received FDA clearance for prostate cancer and urologic procedures, respectively, demonstrating high effectiveness and safety.
"We will be looking not only at how well this software performs in a busy clinical setting and whether diagnostic accuracy and efficiency improves, but also assessing the experience of clinicians and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback